Machine Learning-Based Detection of Egfr Mutation and Her2 Overexpression in Metastatic Brain Adenocarcinoma: Systematic Review and Meta-Analysis Publisher Pubmed



Gholami Chahkand MS ; Karimi MA ; Aghazadehhabashi K ; Esmaeilpour Moallem F ; Mehrabanpour R ; Dadkhah PA ; Esmailinia R ; Esfandiari N ; Azarm E ; Rafiei SKS ; Asadi Anar M ; Shahriari A
Source: Topics in Magnetic Resonance Imaging Published:2025

Abstract

BACKGROUND AND AIM: Brain metastases (BMs) are the most common intracranial malignancy, often arising from lung, breast, and melanoma cancers. Receptor tyrosine kinases, such as EGFR and HER2, drive tumor progression and resistance to therapy. Noninvasive detection of these biomarkers, especially in brain metastases, is crucial due to challenges with traditional biopsy methods. This systematic review and meta-analysis assess machine learning (ML)-based models for detecting EGFR mutations and HER2 overexpression in metastatic brain adenocarcinoma using MRI-derived radiomic features. METHODS: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. Studies were identified via PubMed, Scopus, and Web of Science, focusing on ML applications to MRI radiomics for detecting EGFR and HER2 in brain metastases. Data on study design, imaging modality, model type, sample size, and performance metrics were extracted. Subgroup analyses were performed by model type (deep learning vs. classical ML) and sample size (<150 vs. ≥150 participants). A random-effects model was used to pool performance metrics, and risk of bias was assessed using the RoB 2 tool. STATA version 18 and Python 3.10 were used for analyses and visualizations. RESULTS: Of 383 identified studies, 31 (7925 participants) met the inclusion criteria. The pooled analysis showed strong diagnostic performance: AUC = 0.84, accuracy = 0.86, and sensitivity = 0.83. Subgroup analysis revealed higher AUC and accuracy in deep learning models compared with classical ML. Sensitivity analysis also indicated improved AUC in studies with larger sample sizes (≥150), though variability remained. No evidence of heterogeneity or publication bias was detected. CONCLUSION: ML models demonstrate strong diagnostic performance for detecting EGFR and HER2 in metastatic brain adenocarcinoma, supporting their potential as noninvasive diagnostic tools. However, these findings should be interpreted considering methodological heterogeneity and the limited use of external validation. Further prospective, multicenter studies are warranted to confirm their clinical applicability and generalizability. This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine